Impact of Guideline-Directed Statin Prescriptions on Cardiovascular Outcomes by Race in a Real-World Primary Prevention Cohort
Authors' conclusion
Although Black patients received proportionally less statin prescription than White patients, this was not associated with higher risk of mortality in Black patients.
Study context
- Population
- Black and White patients without atherosclerotic cardiovascular disease (ASCVD) in a large nongovernmental health care system, 2013–201920,477 Black
- Participants
- 270,079 participants
- Exposure
- No statin vs guideline-directed statin intensity, within and across race
- Outcome
- Incident ASCVD events:
- MI/revascularization
- Stroke
- Mortality
- Follow-up
- Mean 6 years
Methodological detailsreal-world primary prevention cohort, electronic health records, Cox regression adjusted for CVD risk factors
- Real-world primary prevention cohort
- Electronic health records
- Cox regression adjusted for CVD risk factors
Main finding
As reported in the abstract
Incident ASCVD, no statin vs guideline-directed statin intensity, by race
No statin vs Guideline-directed statin intensityHazard ratio (95% CI)P value
Black patients
1.40(1.05–1.86)
White patients
1.32(1.21–1.45)
P < 0.05Observational data: associations, not effects.
Further findings
Statin prescription, by race
P < 0.001
All-cause mortality, no statin vs guideline-directed statin intensity · mean follow-up 6 years
- Increased all-cause mortality with no statin in Black and White patients
Mortality, intermediate and high-risk Black vs White patients (subgroup)
- 17% higher risk of mortality in Black vs White patients
Original publication
Impact of Guideline-Directed Statin Prescriptions on Cardiovascular Outcomes by Race in a Real-World Primary Prevention Cohort. JACC Adv. Published 10 September 2024. doi:10.
Summarised from the published abstract; every number is checked against it